Independent directory Public ClinicalTrials.gov records United States
Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 2, 2026, 2:26 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 49–72 of 179 matching trials from the live ClinicalTrials.gov search.
Completed Not applicable Interventional Results available

Natural Killer (NK) Cell Transplantation for AML

NCT00187096
Conditions
Acute Myeloid Leukemia
Interventions
Cyclophosphamide, Fludarabine, Clofarabine, Etoposide, Interleukin-2, Natural Killer Cell Infusion, CliniMACS System
Drug · Procedure · Device
Lead sponsor
St. Jude Children's Research Hospital
Other
Eligibility
Up to 21 Years
Enrollment
49 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2013
U.S. locations
1
States / cities
Memphis, Tennessee
Conditions
Lymphoma, Carcinoma
Interventions
rh IL-15 (10 DAYS), rh IL-15 (5 DAYS)
Biological
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
38 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2019
U.S. locations
1
States / cities
Bethesda, Maryland
Conditions
Leukemia, Myeloid, Acute
Interventions
PNK-007, Cyclophosphamide, Fludarabine, Human recombinant Interleukin-2 (rhIL-2)
Biological · Drug
Lead sponsor
Celularity Incorporated
Industry
Eligibility
18 Years to 70 Years
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2017
U.S. locations
7
States / cities
Boston, Massachusetts • Minneapolis, Minnesota • Hackensack, New Jersey + 4 more
Conditions
Systemic Lupus Erythematosus
Interventions
NKX019, Cyclophosphamide LD
Biological · Drug
Lead sponsor
Hospital for Special Surgery, New York
Other
Eligibility
18 Years to 65 Years
Enrollment
6 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2040
U.S. locations
2
States / cities
New York, New York
Conditions
Acute Myeloid Leukemia, Myelodysplastic Syndrome
Interventions
Preparative Regimen, NK Cells, Interleukin-2, CD34 Graft/Anti-thymocyte globulin, Donor TCR α/β-depleted Graft/ATG
Drug · Biological
Lead sponsor
Masonic Cancer Center, University of Minnesota
Other
Eligibility
18 Years to 75 Years
Enrollment
25 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2017
U.S. locations
4
States / cities
Atlanta, Georgia • Minneapolis, Minnesota • St Louis, Missouri + 1 more
Completed Phase 1 Interventional Accepts healthy volunteers

Ph I Trial of NAM NK Cells and IL-2 for Adult Pts With MM and NHL

NCT03019666
Conditions
Multiple Myeloma, Non-Hodgkin Lymphoma, Diffuse Large B Cell Lymphoma, Mantle-Cell Lymphoma, Follicular Lymphoma, Indolent B Cell Lymphoma, Primary Mediastinal Lymphoma, Lymphoplasmacytic Lymphoma
Interventions
Nicotinamide Expanded Haploidentical or Mismatched Related Donor Natural Killer Cells
Biological
Lead sponsor
Masonic Cancer Center, University of Minnesota
Other
Eligibility
18 Years to 70 Years
Enrollment
39 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017 – 2022
U.S. locations
1
States / cities
Minneapolis, Minnesota
Conditions
Leukemia, Lymphoma, Multiple Myeloma and Plasma Cell Neoplasm
Interventions
busulfan, cyclophosphamide, Stem cell infusion, Total body irradiation
Drug · Biological · Radiation
Lead sponsor
Masonic Cancer Center, University of Minnesota
Other
Eligibility
Up to 55 Years
Enrollment
6 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1999 – 2019
U.S. locations
1
States / cities
Minneapolis, Minnesota
Conditions
Acute Myeloid Leukemia
Interventions
SAR443579, venetoclax, azacitidine
Biological · Drug
Lead sponsor
Sanofi
Industry
Eligibility
18 Years and older
Enrollment
7 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2025
U.S. locations
5
States / cities
Duarte, California • The Bronx, New York • Columbus, Ohio + 2 more
Conditions
Leukemia, Lymphoma
Interventions
aldesleukin, allogeneic natural killer cells, rituximab, cyclophosphamide, fludarabine phosphate
Biological · Drug
Lead sponsor
Masonic Cancer Center, University of Minnesota
Other
Eligibility
18 Years and older
Enrollment
6 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2010
U.S. locations
1
States / cities
Minneapolis, Minnesota
Conditions
Gastric Cancer, Metastatic
Interventions
TGFBR2 KO CAR27/IL-15 NK cells, Rimiducid (AP1903), Fludarabine, Cyclophosphamide
Drug
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years and older
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2030
U.S. locations
1
States / cities
Houston, Texas
Conditions
Hematologic Malignancies
Interventions
Haplo HCT ≥55 years old, GVHD Prophylaxis, Haplo HCT ≥55 and < 65 years old, Haplo HCT ≥65 and ≤75 years old
Biological · Drug
Lead sponsor
Masonic Cancer Center, University of Minnesota
Other
Eligibility
Up to 75 Years
Enrollment
78 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2025
U.S. locations
1
States / cities
Minneapolis, Minnesota
Conditions
Leukemia, Chronic Myelogenous Leukemia
Interventions
Fludarabine, Busulfan, NK cell infusion:, Interleukin-2, Anti-Thymocyte Globulin, Allogeneic related Stem Cell Transplant, Tacrolimus, Methotrexate, G-CSF
Drug · Procedure
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
Up to 70 Years
Enrollment
6 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2014
U.S. locations
1
States / cities
Houston, Texas
Conditions
Leukemia, Myelodysplastic Syndromes
Interventions
aldesleukin, filgrastim, natural killer cell (NK) therapy, cyclophosphamide, cyclosporine, fludarabine phosphate, methylprednisolone, mycophenolate mofetil, Umbilical Cord Blood Transplantation (UCBT), Total body irradiation (TBI)
Biological · Drug · Procedure + 1 more
Lead sponsor
Masonic Cancer Center, University of Minnesota
Other
Eligibility
Up to 45 Years
Enrollment
16 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2008
U.S. locations
1
States / cities
Minneapolis, Minnesota
Conditions
Astrocytoma, Glioblastoma, Progressive Disease
Interventions
FT536, Biopsy/ Intratumoral Injection/ Gross Tumor Resection, Blood/ Cerebrospinal Fluid/ Tumor Pathology
Biological · Procedure · Diagnostic Test
Lead sponsor
Masonic Cancer Center, University of Minnesota
Other
Eligibility
18 Years to 75 Years
Enrollment
9 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2029
U.S. locations
1
States / cities
Minneapolis, Minnesota
Conditions
Multiple Myeloma
Interventions
Elotuzumab, Melphalan, Autologous Stem Cell Transplant (ASCT), Expanded Natural Killer (ENK) Cells, ALT-803
Drug · Procedure · Biological
Lead sponsor
University of Arkansas
Other
Eligibility
18 Years to 75 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2020
U.S. locations
1
States / cities
Little Rock, Arkansas
Conditions
HIV-1-infection, ART, Cd4+ Lymphocyte Deficiency, Lymphoid Tissue; Infection, Interleukin
Interventions
FT538, Vorinostat
Biological · Drug
Lead sponsor
Masonic Cancer Center, University of Minnesota
Other
Eligibility
18 Years to 65 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024
U.S. locations
1
States / cities
Minneapolis, Minnesota
Conditions
Acute Myelogenous Leukemia
Interventions
aldesleukin, natural killer cells, cyclophosphamide, fludarabine phosphate, allogeneic hematopoietic stem cell transplantation, total body irradiation, Thymoglobulin, Cyclosporin A
Biological · Drug · Procedure + 1 more
Lead sponsor
Masonic Cancer Center, University of Minnesota
Other
Eligibility
18 Years to 70 Years
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2011
U.S. locations
1
States / cities
Minneapolis, Minnesota
Conditions
Pediatric Sarcoma, Refractory, Pediatric Sarcoma, Relapsed
Interventions
GEM/DOX + TGFBi expanded NK cells
Biological
Lead sponsor
Nationwide Children's Hospital
Other
Eligibility
2 Years to 40 Years
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2027
U.S. locations
22
States / cities
South Birmingham, Alabama • Phoenix, Arizona • Little Rock, Arkansas + 19 more
Conditions
Leukemia, Myelogenous, Acute
Interventions
Natural Killer Cells, Fludarabine, Cyclophosphamide, Denileukin diftitox, Donor lymphapheresis, IL-2
Biological · Drug · Procedure
Lead sponsor
Masonic Cancer Center, University of Minnesota
Other
Eligibility
2 Years and older
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2012
U.S. locations
1
States / cities
Minneapolis, Minnesota
Completed Phase 2 Interventional Results available

Therapy for Children With Advanced Stage Neuroblastoma

NCT01857934
Conditions
Neuroblastoma
Interventions
cyclophosphamide, topotecan, hu14.18K322A, peripheral blood stem cell harvest, surgical resection, cisplatin, etoposide, doxorubicin, vincristine, busulfan, melphalan, peripheral blood stem cell transplantation, natural killer cell infusion, radiation therapy, GM-CSF, G-CSF, mesna, levetiracetam, interleukin-2, Isotretinoin, CliniMACS
Drug · Biological · Procedure + 2 more
Lead sponsor
St. Jude Children's Research Hospital
Other
Eligibility
Up to 18 Years
Enrollment
153 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2025
U.S. locations
1
States / cities
Memphis, Tennessee
Conditions
Advanced Renal Cell Carcinoma, Advanced Mesothelioma, Advanced Osteosarcoma
Interventions
CAR.70/IL15-transduced CB-derived NK cells, Fludarabine phosphate, Cyclophosphamide
Drug
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
16 Years to 80 Years
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2027
U.S. locations
1
States / cities
Houston, Texas
Conditions
Lymphoma, Leukemia, Transplantation, Stem Cell, Lymphoid Malignancies, Disorder Related to Transplantation
Interventions
GM-CSF, Rituximab, NK Cell Infusion
Drug · Biological
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
Not listed
Enrollment
6 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2019
U.S. locations
1
States / cities
Houston, Texas
Conditions
B-Lymphoid Malignancies, Acute Lymphocytic Leukemia, Chronic Lymphocytic Leukemia, Non-hodgkin Lymphoma
Interventions
Fludarabine, Cyclophosphamide, Mesna, iC9/CAR.19/IL15-Transduced CB-NK Cells, AP1903
Drug · Biological
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
7 Years to 80 Years
Enrollment
49 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2023
U.S. locations
1
States / cities
Houston, Texas
Conditions
Leukemia, Myelodysplastic Syndromes
Interventions
anti-thymocyte globulin, fludarabine phosphate, thiotepa, peripheral blood stem cell transplantation, total-body irradiation
Biological · Drug · Procedure + 1 more
Lead sponsor
Masonic Cancer Center, University of Minnesota
Other
Eligibility
Up to 60 Years
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2011
U.S. locations
9
States / cities
Tampa, Florida • Atlanta, Georgia • Indianapolis, Indiana + 5 more